Linear mixed model estimates for the clinical SELENA-SLEDAI and PGA in relation to laboratory measures by multivariate analysis
| Model | Outcome variable | Predictors | Slope estimate; p values | Marginal R2 (%) |
| EC4d + low C3/C4 | Clinical SELENA-SLEDAI | Intercept | 1.53±0.75; | 7.7 |
| EC4d (log net MFI)+ | 0.94±0.28; p<0.01* | |||
| Low complement C3/C4 | 1.24±0.43; p<0.01 | |||
| PGA | Intercept | 0.64±0.10; | 9.1 | |
| EC4d (log net MFI)+ | 0.12±0.04; p< 0.01 | |||
| Low complement C3/C4 | 0.24±0.06; p<0.01 | |||
| EC4d + low C3/C4 +anti-dsDNA | Clinical SELENA-SLEDAI | Intercept | −0.53±0.12; | 19.6 |
| EC4d (log net MFI)+ | 0.49±0.28; p=0.07 | |||
| Low complement C3/C4+ | 0.79±0.43; p=0.07 | |||
| Anti-dsDNA (log net MFI) | 0.90±0.17; p=0.01 | |||
| PGA | Intercept | 0.52±0.12; | 12.3 | |
| EC4d (log net MFI)+ | 0.09±0.04; p = 0.03 | |||
| Low complement C3/C4+ | 0.20±0.06; p< 0.01 | |||
| Anti-dsDNA (log net MFI) | 0.06±0.02; p = 0.01 |
Intercept, slope estimates, p values and marginal R2 are given.
*One log EC4d levels and low complement C3/C4 were associated with a 0.9-point and 1.2-point in clinical SELENA-SLEDAI, respectively; presence of both one log EC4d levels and low complement C3/C4 was associated with 2.1-point clinical SELENA-SLEDAI.
dsDNA, double-stranded DNA; EC4d, erythrocyte- bound C4d; MFI, mean fluorescence intensity; PGA, Physicians Global Assessment; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment— SLE Disease Activity Index.